Pharmasyntez to build Russia's largest hormonal drugs production plant
Pharmasyntez, one of Russia’s largest drugmakers, has announced its plans to build the largest production facility for hormonal drugs in the country, that will be located in the Tyumen region, according to the company, reports The Pharma Letter’s local correspondent.
The new facility will be located on a 25,000 sq meter site and will produce 16 items of various drugs. The value of investment in the project will amount to 3 billion roubles ($45 million). The new facility will also be one of the largest in terms of output in Europe.
According to Vikram Punia, president of JSC Pharmasyntez, the current situation with hormonal drugs in Russia remains complex, as domestic production covers only 5% of local needs, with the remaining requirements being met by imports.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze